In collaboration with Fairview Health Services and University of Minnesota Health in the US, Proteus Digital Health has launched digital medicines to boost outcomes for cancer patients.
The digital oncology medicines are intended to support treatment regimens and aid patients in completing oral chemotherapy cycles.
In addition, the products will offer insights into patients’ treatment progress and overall health status.
The partners developed a care model for oral digital oncology medicines.
Fairview Health has become the first organisation to prescribe digital capecitabine, a chemotherapy drug, for use with the Proteus ingestible sensor.
Currently, the digital medicine is being used to help treat patients with stage 3 and 4 colorectal cancer.
Proteus Digital Health CEO and co-founder Andrew Thompson said: “For the first time, digital oncology medicines give providers and caregivers new insights and ability to engage with more specific information in the remote care of colorectal cancer patients.
“Based on our data around the use of digital medicines in other treatment areas, we believe this will enable oncology patients to stay on their therapy longer, avoid hospital admissions, and have better response to therapy overall.”
The digital medicines programme is designed to capture, record and share information regarding the time, dose and type of oral chemotherapy medication taken by the patient.
Patients can choose to share the medication information as well as data on rest, activity and resting heart rate with their physician, pharmacist or caretaker on a secure platform developed by Proteus.
Proteus is additionally introducing a digital oral oncolytic medication registry in order to collect more real-world data from cancer patients using digital medicines.
The study will gather information from several sites, where patients will be prescribed digital capecitabine to aid their treatment.
Study findings will be used to share best practices across multiple sites, enabling enhanced data and outcome analysis.